Evidence map›Paper›PMID 23582414›Full record

Trial reportInternational journal of cardiology2013

Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT).

Christopher B Overgaard, Vladimír Džavík, Christopher E Buller, Li Liu, Waldemar Banasiak, Gerard Devlin, Aldo P Maggioni, Jonathan Leor, Jeffery R Burton, Gilmar Reis and 5 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in International journal of cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 6 countries.

Christopher B OvergaardPeter Munk Cardiac Centre, University Heath Network, Toronto, Ontario, Canada.
Vladimír Džavík
Christopher E Buller
Li Liu
Waldemar Banasiak
Gerard Devlin
Aldo P Maggioni
Jonathan Leor
Jeffery R Burton
Gilmar Reis
Witold Ruzyllo
Sandra A Forman
Gervasio A Lamas
Judith S Hochman
OAT Investigators
Clinical Trials and Surveys Corporation · USUniversity Health Network · CAAssociazione Nazionale Medici Cardiologi Ospedalieri · ITGrupo Santa Casa de Belo Horizonte · BRInstitute of Cardiology · PLMount Sinai Medical Center · USNew York University · USSt. Michael's Hospital · CAUniversity of Alberta · CAWaikato Hospital · NZ

Funding

Occluded Artery Trial: Long Term Follow-UpU01HL062509 · NHLBI · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI HOCHMAN, JUDITH S · 1999 to 2010
$11.1M
Occluded Artery Trial: Long-Term Follow up-Data Coordinating CenterU01HL062511 · NHLBI · MARYLAND MEDICAL RESEARCH INSTITUTE, INC · PI FORMAN, SANDRA · 1999 to 2010
$5.2M
NHLBI NIH HHS U01 HL062509NHLBI NIH HHS U01HL062509NHLBI NIH HHS U01 HL062511NHLBI NIH HHS U01HL062511
6 · The paper itself

Abstract

backgroundPercutaneous coronary intervention (PCI) of a persistently totally occluded infarct-related artery (IRA) in stable high-risk patients >24h after myocardial infarction (MI) does not reduce the occurrence of death, re-infarction, or heart failure. Diabetic patients are at higher risk for cardiovascular events; we examined their outcomes overall with PCI and optimal medical therapy alone (MED).

methodsThe long-term (7-year) outcomes of 454 diabetic patients (20.6%) randomized to PCI or MED in the Occluded Artery Trial (OAT) were assessed for the composite primary endpoint of death, re-MI, or New York Heart Association class IV heart failure. Diabetics and non-diabetics were compared and outcomes assessed by treatment strategy.

resultsThe 7-year cumulative primary event rate for diabetic patients was 35.0% vs. 19.4% in the non-diabetic cohort (p<0.001). Multivariable analyses revealed diabetes to be an independent predictor (p<0.01) for the primary outcome, fatal or nonfatal recurrent MI, Class IV Heart Failure (HF), and death. The 7-year cumulative primary event rates were 35.3% in the PCI group vs. 34.5% in the medical therapy group in diabetic patients (p=0.19) and 19.3% in the PCI group vs. 19.5% in the medical therapy group in patients without diabetes (p=0.60).

conclusionsDespite the higher overall risk conferred by the presence of diabetes, PCI did not improve clinical outcomes in this subpopulation, and is not indicated in otherwise stable patients with a totally occluded infarct-related artery in the sub-acute phase after MI.

Indexed as

Percutaneous Coronary InterventionCoronary OcclusionDiabetic AngiopathiesFemaleHumansMaleMiddle AgedMyocardial InfarctionTime FactorsTreatment OutcomeDiabetesOccluded arteryOpen artery hypothesisPercutaneous coronary intervention

Identifiers

PMID23582414
PMCPMC10515322
OpenAlexW2054138898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.